Health Care • Medical/Dental Instruments
$85.74 ▲ +1.81
(+2.16%)
MKT CAP: $1.10B • VOL: 92.6K
52W L $76 52W H $108
ROARABLE / RQD
C+ • 68/100
PIOTROSKI
8 / 9
IRMD // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $83.8M | $73.2M | $65.6M |
| YoY Revenue Growth % | +14.4% | +11.7% | — |
| Gross Profit | $64.3M | $56.4M | — |
| Gross Margin % | 76.7% | 76.9% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $26.1M | $22.0M | $20.0M |
| Operating Margin % | 31.2% | 30.0% | 30.6% |
| Net Income (GAAP) | $22.5M | $19.2M | $17.2M |
| EBITDA (Normalized) | $32.4M | $28.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $24.9M | $25.6M | $13.5M |
| Capital Expenditures (CapEx) | $7.8M | $8.0M | — |
| Free Cash Flow (FCF) | $17.2M | $17.6M | $13.5M |
| FCF Margin % | 20.5% | 24.1% | 20.5% |
| Return on Invested Capital (ROIC %) | 47.5% | 50.2% | — |
| Cash & Short-Term Equivalents | $51.2M | $52.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $94.6M | $86.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR IRMD.